TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21685354
Drug: Emergent literacy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emergent literacy intervention consisting of eighteen 30‐min lessons delivered twice weekly to small groups of children.
Study: 11098560
Drug: Amiodarone or
Normalized name: amiodarone Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiodarone or new class III agents (e.g., Dofetilide)
Study: 8775936
Drug: Antiarrhythmic agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiarrhythmic agents
Study: 9328156
Drug: Clodronate (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clodronate (300 mg/day i.v. for 5 days followed by 1.6 g/day orally for 12 months)
Study: 8104200
Drug: Idazoxan (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Idazoxan (mean dose, 120 mg/day) combined with fluphenazine (mean dose, 28 mg/day)
Study: 4042078
Drug: Ethyl loflazepate
Normalized name: ethyl loflazepate
DrugBank: Ethyl loflazepate (DB01545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethyl loflazepate 2 mg
Study: 4042078
Drug: Ethyl loflazepate
Normalized name: ethyl loflazepate
DrugBank: Ethyl loflazepate (DB01545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethyl loflazepate 4 mg
Study: 4042078
Drug: Ethyl loflazepate
Normalized name: ethyl loflazepate
DrugBank: Ethyl loflazepate (DB01545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethyl loflazepate 6 mg
Study: 4042078
Drug: Ethyl loflazepate
Normalized name: ethyl loflazepate
DrugBank: Ethyl loflazepate (DB01545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethyl loflazepate 8 mg
Study: 28984097
Drug: Intraoperative epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative epidural infusion started preoperatively and maintained throughout
Study: 28984097
Drug: Postoperative initiation
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Postoperative initiation of epidural infusion after neurological examination
Study: 27655371
Drug: Frontal electromyographic
Normalized name: Bos taurus frontal lobe preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Frontal electromyographic (EMG) biofeedback associated with prophylactic pharmacological therapy
Study: 27655371
Drug: Pharmacological treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacological treatment alone (Control Group)
Study: 20601737
Drug: Sodium bicarbonate
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium bicarbonate (NaHCO3) ingestion at a dosage of 0.3 g/kg
Study: 15647411
Drug: Posaconazole 400
Normalized name: Posaconazole
DrugBank: Posaconazole (DB01263)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Posaconazole 400 mg oral suspension
Study: 15647411
Drug: Posaconazole 400
Normalized name: Posaconazole
DrugBank: Posaconazole (DB01263)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Posaconazole 400 mg oral suspension (hemodialysis-dependent subjects)
Study: 14512128
Drug: Budesonide aqueous
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide aqueous nasal spray (BANS) - 64-microg total dose (one 32-microg spray per nostril)
Study: 14512128
Drug: Budesonide aqueous
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide aqueous nasal spray (BANS)
Study: 14512128
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate nasal spray (FPNS) - 200-microg total dose (two 50-microg sprays per nostril in study 1) and 100-microg total dose (one 50-microg spray per nostril in study 2)
Study: 10580711
Drug: Pulsed high-frequency
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pulsed high-frequency electromagnetic field (EMF) exposure (900 MHz; maximum specific absorption rate 1 W/kg) during night-time sleep
Study: 1895262
Drug: Cyclosporine (initial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine (initial daily dose 5 mg/kg)
Study: 1895262
Drug: D-penicillamine (initial
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-penicillamine (initial daily dose 250 mg)
Study: 31729326
Drug: Immediate blood
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate blood transfusion (higher volume: 30 mL/kg whole blood / 15 mL/kg packed cells; lower volume: 20 mL/kg whole blood / 10 mL/kg packed cells)
Study: 31729326
Drug: Immediate blood
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate blood transfusion (20 mL/kg whole blood equivalent)
Study: 28323798
Drug: FiO2 80%
Approvals — FDA: no, EMA: no, PMDA: no
Description: FiO2 80% (Supplemental perioperative oxygen therapy)
Study: 26515269
Drug: Oral melatonin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral melatonin (0.5 mg/kg)
Study: 24486687
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 0.2% Glyceryl Trinitrate and 2% lignocaine ointment (Group A)
Study: 24486687
Drug: 2% lignocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% lignocaine ointment (Group B)
Study: 24486687
Drug: 0.2% Glyceryl
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2% Glyceryl Trinitrate ointment (Group C)
Study: 17244902
Drug: Repetitive low-energy
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repetitive low-energy shock-wave therapy (SWT)
Study: 15978302
Drug: Ipratropium/albuterol 36/206
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ipratropium/albuterol 36/206 microg QID (IB/ALB)
Study: 12785670
Drug: Control period
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control period of traditional treatment
Study: 10234599
Drug: Ganciclovir 1000
Normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ganciclovir 1000 mg q8h with zalcitabine 0.75 mg q8h
Study: 10234599
Drug: Ganciclovir 1000
Normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ganciclovir 1000 mg q8h with stavudine 40 mg q12h
Study: 10234599
Drug: Ganciclovir 1000
Normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ganciclovir 1000 mg q8h alone
Study: 8598547
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg vitamin A (retinyl palmitate)
Study: 1959720
Drug: Inhaled fenoterol,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled fenoterol, 0.2 mg 4 times daily for 7 days
Study: 19281636
Drug: Two doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses of 40 mg/kg praziquantel with 2 weeks interval
Study: 19281636
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 40 mg/kg praziquantel
Study: 10636605
Drug: Psychosocially enhanced
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychosocially enhanced treatment program (PET)
Study: 10636605
Drug: Case management-oriented
Approvals — FDA: no, EMA: no, PMDA: no
Description: Case management-oriented outpatient treatment program (CM)
Study: 21806904
Drug: Parental presence
Normalized name: C.I. direct red 28 parent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parental presence during dental treatment
Study: 8417772
Drug: Parental absence
Normalized name: C.I. direct red 28 parent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parental absence during dental treatment
Study: 3804028
Drug: Cimetidine plus
Normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cimetidine plus sulpiride 200 mg daily
Study: 29356277
Drug: New complex
Normalized name: TITANIUM DIOXIDE 4 mg in 1 mL TOPICAL PASTE [Revlon New Complexion One-Step Perfect Make-Up]
Approvals — FDA: no, EMA: no, PMDA: no
Description: New complex cream composed of Yunnan Portulaca oleracea extract, Prinsepia utilis oil, beta‐glucan, and sodium hyaluronate, applied twice daily for 28 days.
Study: 29356277
Drug: Control cream
Normalized name: BENZOYL PEROXIDE 3 mg in 60 mL TOPICAL LIQUID [Acnecare Dermacontrol Cream]
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control cream (tolerance‐extreme cream), applied twice daily for 28 days.
Study: 29356277
Drug: New complex
Normalized name: TITANIUM DIOXIDE 4 mg in 1 mL TOPICAL PASTE [Revlon New Complexion One-Step Perfect Make-Up]
Approvals — FDA: no, EMA: no, PMDA: no
Description: New complex cream
Study: 29231520
Drug: Quick needle
Normalized name: Cal-Quick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quick needle insertion therapy at Aqiang point
Study: 24758164
Drug: Individualised audit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualised audit and feedback (A&F) strategies for antibiotic prescribing
Study: 17058829
Drug: Acupuncture therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture therapy (DFIPRS) in addition to anti-asthmatic medicine
Study: 17058829
Drug: Anti-asthmatic medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-asthmatic medicine only (control group)
Study: 10834678
Drug: Dopamine at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopamine at a renal dose (2.5 microg/kg/min)
Study: 10834678
Drug: Dopamine at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopamine at higher doses (10 microg/kg/min)
Study: 8800254
Drug: Veterinarians enrolled
Normalized name: Enromed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Veterinarians enrolled in a dairy production medicine continuing education program (treatment herds)
Study: 1364078
Drug: Clozapine (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clozapine (500 mg/day)
Study: 1364078
Drug: Chlorpromazine (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorpromazine (600 mg/day)
Study: 6370976
Drug: Nomifensine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nomifensine (150 mg/day)
Study: 25022939
Drug: Rotigotine transdermal
Normalized name: Rotigotine Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rotigotine transdermal patches (maximum maintenance dose of 16 mg/24 h)
Study: 25022939
Drug: Rotigotine transdermal
Normalized name: Rotigotine Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rotigotine transdermal patches
Study: 20009770
Drug: SPIRO 50
Normalized name: 4-Deoxo-3,4-(2-spiro(N-isobutyl-4-piperidyl)-2,5-dihydro-1H-imidazo)-rifamycin S
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPIRO 50 mg once daily for 12 weeks
Study: 20009770
Drug: BFZ 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: BFZ 2.5 mg once daily for 12 weeks
Study: 20009770
Drug: SPIRO 50
Normalized name: 4-Deoxo-3,4-(2-spiro(N-isobutyl-4-piperidyl)-2,5-dihydro-1H-imidazo)-rifamycin S
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPIRO 50 mg
Study: 20009770
Drug: BFZ 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: BFZ 2.5 mg
Study: 15926441
Drug: Computerized injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computerized injection device
Study: 10351924
Drug: Zafirlukast (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zafirlukast (20 mg twice a day)
Study: 10351924
Drug: Beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone dipropionate (200 microg twice a day)
Study: 7496001
Drug: Triple combination
Normalized name: Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple combination of 50 mg isoniazid + 120 mg rifampicin + 300 mg pyrazinamide
Study: 7496001
Drug: Separate administration
Normalized name: Atractylis separate root
DrugBank: Atractylodes lancea root (DB14693)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Separate administration of the 3 antituberculosis drugs
Study: 7496001
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (triple combination and separate drugs)
Study: 7006544
Drug: 1 mL/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mL/kg of 50% dextrose in water (D50W)
Study: 31726963
Drug: Clopidogrel-Aspirin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel-Aspirin therapy
Study: 29047413
Drug: VHA-guided transfusion
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: VHA-guided transfusion therapy
Study: 29047413
Drug: CCT-guided transfusion
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CCT-guided transfusion therapy
Study: 29047413
Drug: CCT-guided therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: CCT-guided therapy
Study: 29047413
Drug: VHA-guided therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: VHA-guided therapy
Study: 21646441
Drug: Pregabalin add-on
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pregabalin add-on therapy
Study: 17536120
Drug: EGCG (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: EGCG (300 mg)
Study: 17536120
Drug: EGCG (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: EGCG (150 mg twice daily for two weeks)
Study: 17536120
Drug: EGCG (acute
Approvals — FDA: no, EMA: no, PMDA: no
Description: EGCG (acute treatment)
Study: 17536120
Drug: EGCG (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: EGCG (two weeks treatment)
Study: 15467101
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose Cr-pic
Study: 11426898
Drug: Sildenafil 25
Normalized name: sildenafil 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil 25 mg and 50 mg
Study: 11120458
Drug: Enalapril (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (0.25 mg/kg/day)
Study: 9105164
Drug: C II
Normalized name: Xedec II
Approvals — FDA: no, EMA: no, PMDA: no
Description: C II treatment (chicken cartilage soup containing heat degenerated C II)
Study: 2951824
Drug: Ipratropium bromide,
Normalized name: Ipratropium Bromide, compounding powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ipratropium bromide, 0.5 mg + fenoterol, 2.0 mg
Study: 27018896
Drug: Local administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Local administration of depomedrol
Study: 20201624
Drug: Internet-based coaching,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based coaching, daily use of proprietary olfactive-based personal care products, and periodic feedback reports (Group 1)
Study: 10080400
Drug: Polyclonal antibody
Normalized name: Polyclonal antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyclonal antibody ATG for DGF
Study: 8530600
Drug: Sublingual testosterone
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sublingual testosterone cyclodextrin (SLT; 2.5 mg, administered three times per day)
Study: 8530600
Drug: Sublingual testosterone
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sublingual testosterone cyclodextrin (SLT; 5.0 mg, administered three times per day)
Study: 8530600
Drug: Testosterone enanthate
Normalized name: Testosterone Enanthate
DrugBank: Testosterone enanthate (DB13944)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone enanthate (TE; 200 mg, given once every 20 days by IM injections)
Study: 28806532
Drug: Oral phosphate
Normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral phosphate load (PHOS; liquid supplement containing 1200 mg of phosphorus)
Study: 28806532
Drug: Oral phosphate
Normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral phosphate load (PHOS)
Study: 24494282
Drug: Acupuncture therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture therapy at specific points (Yaoyangguan, Mingmen, Zhiyang, Shenzhu, Dazhui, Yamen, Fengfu, Baihui, Neck‐Jiaji) given 6 times a week for 21 days.
Study: 21717781
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment (Ashi‐point, Baihui (GV 20), Taiyang (EX‐HN 5), Shuaigu (GB 8), Fengchi (GB 20), Benshen (GB 13), Lieque (LU 7), needles retained for 30 min, once daily, 6 times a week for 4 weeks)
Study: 21717781
Drug: Medication treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication treatment (Flunarizine 10 mg, once every night for 4 weeks)
Study: 11810777
Drug: Endocrine therapy
Normalized name: ENDOCRINE THERAPY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endocrine therapy (oral tamoxifen for five years; premenopausal patients received bilateral ovary ablation followed by tamoxifen for five years)
Study: 11810777
Drug: Chemotherapy (CTX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (CTX + MTX + 5‐Fu + VCR + DXM (CMFVP) or CTX + MTX + 5‐Fu (CMF))
Study: 9569476
Drug: Acellular pertussis
Normalized name: Acellular pertussis vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acellular pertussis vaccine combined with diphtheria and tetanus toxoids (PRP-T)
Study: 2567739
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of 12 mg acrivastine
Study: 2567739
Drug: Colonic administration
Normalized name: colonial bent grass pollen extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colonic administration of 12 mg acrivastine
Study: 1099491
Drug: AN448 (active
Approvals — FDA: no, EMA: no, PMDA: no
Description: AN448 (active drug)
Study: 30904834
Drug: Dexamethasone (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (0.2 mg/kg at the end of the surgical procedure and at day +1, n=611)
Study: 10511768
Drug: Furosemide (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furosemide (1 mg/kg)
Study: 16937132
Drug: Sonic tooth
Normalized name: Sus scrofa tooth preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sonic tooth brushing and oral hygiene instruction
Study: 9330783
Drug: Beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone dipropionate metered-dose inhaler (CFC-free) at 50 micrograms/actuation
Study: 9330783
Drug: Beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone dipropionate metered-dose inhaler (CFC-free) at 100 micrograms/actuation
Study: 9330783
Drug: Beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone dipropionate metered-dose inhaler (CFC-free) at 200 micrograms/actuation
Study: 8222650
Drug: 20 mcg
Normalized name: Caverject 20 MCG Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mcg ethinyl-estradiol (MERCILON)
Study: 8222650
Drug: 30 mcg
Normalized name: Avonex 30 MCG Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mcg ethinyl-estradiol (MARVELON)
Study: 30919948
Drug: Intrathecal (IT)
Normalized name: beractant
DrugBank: Beractant (DB06761)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrathecal (IT) opioid administration with hydromorphone
Study: 28474741
Drug: Metformin +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin + Daclatasvir
Study: 25159700
Drug: MoodCare (telephone-delivered
Approvals — FDA: no, EMA: no, PMDA: no
Description: MoodCare (telephone-delivered cognitive behavioural therapy and risk-reduction programme)
Study: 3297265
Drug: Propafenone (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propafenone (150 mg quid)
Study: 31724253
Drug: US reference
Approvals — FDA: no, EMA: no, PMDA: no
Description: US reference insulin glargine (US IG)
Study: 31724253
Drug: European reference
Approvals — FDA: no, EMA: no, PMDA: no
Description: European reference insulin glargine (EU IG)
Study: 30453494
Drug: Pistacia lentiscus
Normalized name: Pistacia Lentiscus Gum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pistacia lentiscus (PL) supplement (2.8 g/day) for 3 months
Study: 30453494
Drug: Pistacia lentiscus
Normalized name: Pistacia Lentiscus Gum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pistacia lentiscus (PL) supplement
Study: 16182832
Drug: corticosteroid therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: corticosteroid therapy (control group)
Study: 11509496
Drug: Creatine monohydrate
Normalized name: Creatine Monohydrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine monohydrate (20 g/day for 5 days followed by 5 g/day for 3-4 days)
Study: 9506757
Drug: Intravenous cocaine
Normalized name: Cocaine
DrugBank: Cocaine (DB00907)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous cocaine (0.2 mg/kg)
Study: 7522315
Drug: Topical corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical corticosteroids (0.1% fluorometholone for 6 months)
Study: 7522315
Drug: Plasmin inhibitors
Normalized name: plasmin
DrugBank: Fibrinolysin (DB05254)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasmin inhibitors (aprotinin 40 IU/ml for 3 weeks)
Study: 7522315
Drug: Plasmin inhibitors
Normalized name: plasmin
DrugBank: Fibrinolysin (DB05254)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasmin inhibitors (aprotinin)
Study: 3351000
Drug: Fluphenazine decanoate
Normalized name: Fluphenazine Decanoate
DrugBank: Fluphenazine (DB00623)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluphenazine decanoate 12.5 mg intramuscularly every 2 weeks
Study: 21839757
Drug: Theobromine (700
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theobromine (700 mg)
Study: 21839757
Drug: Caffeine (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (120 mg)
Study: 21839757
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of caffeine and theobromine
Study: 15577539
Drug: Emtricitabine 200
Normalized name: emtricitabine 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emtricitabine 200 mg QD
Study: 12407485
Drug: Lamivudine 150
Normalized name: lamivudine 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lamivudine 150 mg BID